The National Amyotrophic Lateral Sclerosis Registry

Study Purpose:

To determine the incidence and prevalence of Amyotrophic Lateral Sclerosis in the US

Disease:

Amyotrophic Lateral Sclerosis (ALS),  Familial ALS,  Sporadic ALS

Study Type:

Observational Study

Study Category:

Epidemiology

Study Status:

Active, currently recruiting

Phase:

Not Applicable

Study Chair(s)/Principal Investigator(s):

Oleg Muravov, MD, PhD (CDC)

Clinicaltrials.gov ID (11 digit #):

NCT01772602

Neals Affiliated?

No

Coordinating Center Contact Information


Oleg Muravov, MD, PhD / .(JavaScript must be enabled to view this email address)
.(JavaScript must be enabled to view this email address) Georgia 30333 United States

Full Study Summary:

The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.

Study Sponsor:

Centers for Disease Control and Prevention

Participant Duration:

Estimated Enrollment:

13,000

Estimated Study Start Date:

09/30/2010

Estimated Study Completion Date:

11/30/2020

Posting Last Modified Date:

02/29/2016

Date Study Added to alsconsortium.org:

01/22/2013
  • More Information

    https://clinicalt...CT01772602&rank=1

  • Eligibility Criteria

    Gender:

    Female, Male

    Minimum Age:

    18

    Maximum Age:

    N/A

    Time since Symptom Onset:

    Time since Diagnosis:

    Can participants use Riluzole?


    Inclusion Criteria:
    ALS cases in the United States
    U.S. citizens 18 years of age or older

  • Site Contact Information

    Centers for Disease Control and Prevention
    Oleg Muravov, MD, PhD / .(JavaScript must be enabled to view this email address) / 770-488-3817
    Atlanta, Georgia 30333
    United States